Guy Ungerechts, MD, PhD
Guy Ungerechts MD, PhD is a medical oncologist trained in the field of oncolytic viruses at Mayo Clinic, Rochester, USA and The Ottawa Hospital Research Institute (OHRI), Ottawa, Canada. He is Deputy Director of the Medical Oncology Department at the National Center for Tumor Diseases (NCT), Heidelberg, Germany. His clinical focus is GI oncology with particular interests in translational medicine and early clinical trials of immuno(viro) therapy.
Since 2008 Guy has headed the Virotherapy group at NCT/DKFZ as an independent researcher and coordinates the German Virotherapy Consortium. He has been responsible for the development and execution of several Phase I/II and III trials with oncolytic viruses derived from different platforms including oncolytic measles virus, vaccinia virus (JX-594), parvovirus H-1 and herpes simplex virus (HSV-1). His group recently demonstrated for the first time that measles virus can be armed with immunomodulatory transgenes encoding for cytokines, immune checkpoint blockade antibodies and bispecific T cell engager (BITEs) for enhanced immunovirotherapy.
Since 2015 he has held an Ontario Institute for Cancer Research (OICR) sponsored clinician-scientist position in Ottawa, Canada. As a staff medical oncologist, he was member of the GI cancer group at The Ottawa Hospital (TOH) between 2015 and 2017. He is an adjunct professor at the University of Ottawa and a PI/affiliated investigator at the OHRI in Dr. John Bell´s research program.
